Roquefort Therapeutics, a biotech company focused on early-stage opportunities in the biotechnology sector,, agreed to acquire Oncogeni, a biotech company developing novel patented cancer medicines. Financial terms were not disclosed. "We are extremely pleased to announce the proposed acquisition of Oncogeni which will position the Company as a material oncology focused biotech company, operating in the high value and high growth oncology segment. The expanded portfolio transforms Roquefort Therapeutics into a multi-indication company with greater upside potential and improved drug development risk mitigation," Stephen West, Roquefort Therapeutics Chairman.